The Effect of Age on the Paraoxonase and Arylesterase Activity of Pregnant Mothers and Their Infants

Journal of Clinical Laboratory Analysis

Volumn 26, Issue 4, 2012, Pages 302-306

  Abuhandan, Mahmut ^a   Cakmak, Alpay ^a   Taskin, Abdullah ^a   Karakaya, Emrah ^b   Kocyigit, Abdurrahim ^a   Kilic, Hatip ^a  

^a HARRAN UNIVERSITY   (Turkey)

^b Vomen's Hospital   (Turkey)

Author keywords

Arylesterase; Newborn infant; Older age pregnancy; Paraoxonase; Younger age pregnancy

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXON; PHENYLACETIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MATERNAL AGE; PARITY; PREGNANCY; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VAGINAL DELIVERY;

ADOLESCENT; ADULT; AGE FACTORS; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; INFANT, NEWBORN; MIDDLE AGED; PREGNANCY;

EID: 84864000799     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21521     Document Type: Article

References (40)

1. Juretić D, Tadijanović M, Rekić B, Simeon-Rudolf V, Reiner E, Baricić M. Serum paraoxonase activities in hemodialyzed uremic patients: Cohort study. Croat Med J 2001;42:146-150.
2. Li WF, Costa LG, Furlong CE. Serum paraoxonase status: A major factor in determining resistance to organophosphates. J Toxicol Environ Health 1993;40:337-346.
3. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-336.
4. Bin Ali A, Zhang Q, Lim YK, Fang D, Retnam L, Lim SK. Expression of major HDL-associated antioxidant PON-1 is gender-dependent and regulated during inflammation. Free Radic Biol Med 2003;34:824-829.
5. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase /arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507.
6. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: Biochemistry, genetics, and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76.
7. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high-density lipoprotein against low-density lipoprotein oxidative modification. FEBS Lett 1998;423:57-60.
8. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598-608.
9. Maron DJ, Ridker PM, Pearson TA, Grundy SM. Dyslipidemia, other risk factors, and the prevention of coronary heart disease. Ch 38. In: Fuster V, Alexander RW, O'Rourke R, editors. Hurst's The Heart, 10th edition. New York: McGraw-Hill; 2001. p 1131-60.
10. Biasioli S, Schiavon R, Petrosino L, et al. Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia. ASAIO J 2003;49:295-299.
11. Seres I, Paragh G, Deschene E, Fulop Jr T, Khalil A. Study of factors influencing the decreased HDL-associated PON1 activity with aging. Exp Gerontol 2004;39:59-66.
12. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138.
13. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon the inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391-395.
14. Shih DM, Gu L, Hama S, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996;97:1630-1639.
15. Sutherland WH, Walker RJ, de Jong SA, van Rij AM, Phillips V, Walker HL. Reduced postprandial serum paraoxonase activity after a meal rich in used cookingfat. Arterioscler Thromb Vasc Biol 1999;19:1340-1347.
16. Pope CN, Liu J. Age-related differences in sensitivity to organophosphorus pesticides. Environ Toxicol Pharmacol 1997;4:309-14.
17. Milochevitch C, Khalil A. Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. Prostaglandins Leukot Essent Fatty Acids 2001;65:241-246.
18. Augustinsson KB, Barr M. Age variation in plasma arylesterase activity in children. Clin Chim Acta 1963;8:568-573.
19. Barzilai A, Yamamoto K. DNA damage responses to oxidative stress. DNA Repair (Amst) 2004;3:1109-1115.
20. Singh NP, Danner DB, Tice RR, et al. Basal DNA damage in individual human lymphocytes with age. Mutat Res 1991;256:1-6.
21. Zanetti M, Capellari, GG, Burekovic Ġ et al. Caloric restriction improves endothelial dysfunction during vascular aging: Effects on nitric oxide synthase isoforms and oxidative stress in rat aorta. Exp Gerontol 2010;45:848-855.
22. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 1997;349:851-852.
23. Nguyen SD, Sok DE. Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action. Free Radic Res 2003;37:1319-1330.
24. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004;37:1304-1316.
25. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26:892-904.
26. Holland N, Furlong C, Bastaki M, et al. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environ Health Perspect 2006;114:985-991.
27. Huen K, Harley K, Brooks J, et al. Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms. Environ Health Perspect 2009;117:1632-1638.
28. Huen K, Harley K, Bradman A, Eskenazi B, Holland N. Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes. Toxicol Appl Pharmacol 2010;244:181-189.
29. Burlina A, Michielin E, Galzigna L. Characteristics and behaviour of arylesterase in human serum and liver. Eur J Clin Invest 1977;7:17-20.
30. Infance-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987;7:660-664.
31. Ordowas JM, Pocovi M, Grande F. Plasma lipids and cholesterol esterification during pregnancy. Obstet Gynecol 1984;63:20-25.
32. Piechota W, Staszewski A. Reference ranges of lipids and apolipoproteins in pregnancy. Eur J Obstet Gynecol Reprod Biol 1992;45:27-35.
33. Fåhraeus L, Larsson-Cohn U, Wallentin L. Plasma lipoproteins including high density lipoprotein subfractions during normal pregnancy. Obstet Gynecol 1985;66:468-472.
34. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994;78:117-141.
35. Kourtis A, Gkiomisi A, Mouzaki M, et al. Apelin levels in normal pregnancy. Clin Endocrinol (Oxf) 2011;75:367-371.
36. Brizzi P, Tonolo G, Esposito F, et al. Lipoprotein metabolism during normal pregnancy. Am J Obstet Gynecol 1999;181:430-434.
37. Punonen R. The relationship between serum oestradiol levels and serum triglyceride, cholesterol and phospholipid levels in normal human pregnancy. Br J Obstet Gynecol 1997;84:834-845.
38. Yildiz A, Sezen Y, Gur M, Yilmaz R, Demirbag R, Erel O. Association of paraoxonase activity and coronary collateral flow. Coron Artery Dis 2008;19:441-447.
39. Yildiz A, Gur M, Yilmaz R, et al. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008;197:257-263.
40. Simon T, Steg PG, Becquemont L, et al. Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther 2011;90:561-567.